- Home
- TYRA vs IART Comparison
TYRA vs IART Comparison
Compare TYRA & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- IART
- Stock Information
- Founded
- TYRA 2018
- IART 1989
- Country
- TYRA United States
- IART United States
- Employees
- TYRA N/A
- IART N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- IART Medical/Dental Instruments
- Sector
- TYRA Health Care
- IART Health Care
- Exchange
- TYRA Nasdaq
- IART Nasdaq
- Market Cap
- TYRA 812.7M
- IART 1.8B
- IPO Year
- TYRA 2021
- IART 1995
- Fundamental
- Price
- TYRA $14.43
- IART $23.02
- Analyst Decision
- TYRA Strong Buy
- IART Sell
- Analyst Count
- TYRA 5
- IART 7
- Target Price
- TYRA $31.00
- IART $24.67
- AVG Volume (30 Days)
- TYRA 201.5K
- IART 515.5K
- Earning Date
- TYRA 11-07-2024
- IART 02-26-2025
- Dividend Yield
- TYRA N/A
- IART N/A
- EPS Growth
- TYRA N/A
- IART N/A
- EPS
- TYRA N/A
- IART N/A
- Revenue
- TYRA N/A
- IART $1,564,920,000.00
- Revenue This Year
- TYRA N/A
- IART $6.71
- Revenue Next Year
- TYRA N/A
- IART $6.20
- P/E Ratio
- TYRA N/A
- IART N/A
- Revenue Growth
- TYRA N/A
- IART 1.45
- 52 Week Low
- TYRA $11.24
- IART $16.81
- 52 Week High
- TYRA $29.60
- IART $45.42
- Technical
- Relative Strength Index (RSI)
- TYRA 42.39
- IART 51.30
- Support Level
- TYRA $13.27
- IART $21.77
- Resistance Level
- TYRA $14.77
- IART $22.78
- Average True Range (ATR)
- TYRA 0.75
- IART 0.77
- MACD
- TYRA 0.07
- IART -0.07
- Stochastic Oscillator
- TYRA 50.19
- IART 52.13
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.